Physician profile
Sajjad Saeed
NPI 1972573681
$3,327.85
in general payments reported to CMS, 2019-2025
21 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $49.92 · 2021: $410 · 2022: $905 · 2023: $526 · 2024: $745 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $837.03 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $663.69 | 2020-2025 | Cabenuva, Dovato |
| Merck Sharp & Dohme LLC | $486.06 | 2021-2025 | Delstrigo, Dificid, Pifeltro |
| Takeda Pharmaceuticals U.S.A., INC. | $383.48 | 2021-2024 | Hyqvia, Cuvitru |
| Insmed, INC. | $325.78 | 2019-2025 | Arikayce, Brinsupri |
| Smith+Nephew, INC. | $89.73 | 2019-2022 | |
| Janssen Products, LP | $79.99 | 2022 | |
| Abbvie INC. | $79.48 | 2023-2025 | Avycaz, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.97 | 2024-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $44.68 | 2024 | |
| Csl Behring | $35.57 | 2025 | Hizentra |
| Paratek Pharmaceuticals, INC. | $35.36 | 2023-2024 | Nuzyra |
| Ferring Pharmaceuticals INC. | $29.85 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Argenx US, INC. | $24.80 | 2024 | Vyvgart |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cashflow Solutions, LLC | $22.31 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Solventum Corporation | $20.05 | 2024 | V.A.C.Instill |
| Janssen Biotech, INC. | $19.32 | 2022 | |
| Lilly USA, LLC | $15.73 | 2025 | Mounjaro |
| Melinta Therapeutics, LLC | $14.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.